secwatch.observer — SEC 8-K summary
======================================

Issuer:     TransMedics Group, Inc. (TMDX)
CIK:        0001756262
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0000950170-23-038077
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TransMedics Q2 revenue $52.5M, up 156% YoY; raises FY 2023 guidance to $180M-$190M
--------------------------------------------------------------------------------

- Net revenue $52.5M in Q2 2023, up 156% from $20.5M YoY; net loss narrowed to $1.0M from $11.5M.
- Full-year 2023 revenue guidance raised to $180M-$190M (93%-103% growth) from prior $160M-$170M.
- U.S. National OCS Program drove ~93% of OCS cases; cash $582.2M after $393M convertible notes offering.
- Gross margin steady at 70%; operating expenses $37.6M vs $24.1M; signed deal to acquire Summit Aviation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1756262/000095017023038077/0000950170-23-038077-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1756262/000095017023038077/tmdx-20230803.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-038077

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer